Ipamorelin is a selective growth hormone secretagogue studied for its interaction with growth hormone pathways. Here is what the evidence says, how it differs from other growth hormone pathway compounds, and what legal access looks like in Australia.
This article is for general educational purposes only and does not constitute medical advice. Ipamorelin is a prescription-only medicine in Australia. Access requires assessment and prescription from an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
Ipamorelin is one of the more frequently searched growth hormone pathway peptides in Australia, partly because it appears so often alongside a complementary growth hormone releasing hormone analogue in online discussions about peptide therapy. Despite being commonly mentioned together with other compounds, ipamorelin is a distinct molecule with its own mechanism, its own research history, and its own specific characteristics that make it of interest in the growth hormone peptide space.
This guide covers what ipamorelin is, how it works, what makes it distinctive compared to other growth hormone secretagogues, what the research has examined, and what legal access looks like in Australia.
A selective pentapeptide growth hormone secretagogue that stimulates growth hormone release through the ghrelin receptor pathway.
Studied for its selectivity in stimulating growth hormone release with reduced impact on cortisol and prolactin levels compared to earlier growth hormone secretagogues.
Schedule 4 prescription-only medicine in Australia. Requires a valid prescription from an AHPRA-registered doctor.
Ipamorelin is a synthetic pentapeptide - meaning it is composed of five amino acids - designed to stimulate the release of growth hormone from the pituitary gland. It belongs to a class of compounds called growth hormone secretagogues, which stimulate the body's own growth hormone production rather than replacing growth hormone directly.
Ipamorelin works through the ghrelin receptor, also known as the growth hormone secretagogue receptor or GHS-R. Ghrelin is a naturally occurring hormone involved in growth hormone regulation, appetite signalling, and metabolic processes. Ipamorelin was specifically designed to interact with this receptor to stimulate growth hormone release.
The characteristic that has made ipamorelin of particular research interest compared to earlier growth hormone secretagogues is its selectivity. Earlier compounds in this class were associated with stimulating the release of other hormones alongside growth hormone - particularly cortisol and prolactin. Elevated cortisol has catabolic effects that can counteract some of the anabolic benefits associated with growth hormone, and elevated prolactin has its own side effect profile.
Research examining ipamorelin has investigated whether it can stimulate growth hormone release with greater selectivity and less impact on cortisol and prolactin compared to earlier compounds. This selectivity profile is one of the primary reasons it has become more commonly used in clinical protocols than some of the earlier generation growth hormone secretagogues it was designed to improve upon.
Ipamorelin works through the ghrelin receptor pathway. Growth hormone releasing hormone analogues work through a separate receptor pathway - the GHRH receptor. These are two different receptor systems that both influence growth hormone secretion from the pituitary.
The rationale for combining a growth hormone secretagogue with a growth hormone releasing hormone analogue is that their complementary mechanisms may produce a more complete stimulation of growth hormone release than either compound alone, since they are activating different receptor pathways simultaneously. Whether a combination approach or a standalone protocol is appropriate for any individual is a clinical decision made by the prescribing doctor.
Standalone versus combination protocols: A growth hormone secretagogue such as ipamorelin can be prescribed on its own where a prescribing doctor determines this is appropriate, or as part of a combination protocol alongside a growth hormone releasing hormone analogue. The specific approach depends on the individual's health history, goals, and the prescribing doctor's clinical assessment. There is no single correct approach that applies to everyone.
Research into ipamorelin has examined its interaction with growth hormone secretion, its selectivity profile relative to earlier growth hormone secretagogues, and the downstream effects of growth hormone stimulation on areas including body composition, bone density markers, tissue repair processes, and metabolic function.
The selectivity question - whether it truly produces more selective growth hormone stimulation with less cortisol and prolactin elevation - has been examined in human subjects, which provides data that is directly applicable to clinical use in ways that purely preclinical animal research does not. This human-level selectivity evidence is one of the reasons the compound is of clinical interest.
Yes, under the same framework that applies to all therapeutic peptides in Australia. Ipamorelin is a Schedule 4 prescription-only medicine. It is legal to access when prescribed by an AHPRA-registered medical practitioner following a clinical assessment, and dispensed through a licensed compounding pharmacy. It cannot be legally purchased without a prescription or sourced from unregulated online channels.
Like other growth hormone pathway compounds, ipamorelin is on the WADA prohibited list for competitive sport. This applies regardless of whether it is accessed through a legitimate prescription. Competitive athletes subject to anti-doping regulations should consult their sport's governing body before using any growth hormone pathway compound.